Targets › CD3E
48 programs from 39 companies in 447 trials: 236 Phase 2, 140 Phase 1, 66 Phase 3, 5 Phase 4; Oncology, Immunology, Metabolic and endocrine; next expected readout Nov 2026.
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. (UniProt, P07766)
Open in Phaseline: the race on CD3E, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Elranatamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 4 | Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma … | May 2027 |
| Regeneron Pharmaceuticals | Linvoseltamab anti-B-cell maturation antigen x anti-CD3 bispecific antibody | BCMA, GPRC5D, CD3E, TNFRSF17 | Phase 4 | Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) … | Aug 2027 |
| Turun Song | BCMA x CD3 Bispecific Antibody BCMA x CD3 bispecific T-cell engager (BiTE) that engages B cells and plasma cells expressi | BCMA, CD3E | Phase 4 | Antibody Mediated Rejection After Kidney Transplantation | Dec 2029 |
| Wuhan YZY Biopharma | M701 anti-EpCAM and anti-CD3 human-mouse chimeric bispecific antibody | EPCAM, CD3E | Phase 3 | Malignant Ascites; Malignant Pleural Effusions | Dec 2026 |
| Roche | Glofitamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma … | Jan 2027 |
| Roche | Mosunetuzumab T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent | CD3E, CD3G, CD3D, MS4A1 | Phase 3 | Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma … | Feb 2027 |
| Genmab | Epcoritamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma … | Mar 2027 |
| Johnson & Johnson (Janssen) | Talquetamab T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent | CD3E, CD3G, CD3D, GPRC5D | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| Johnson & Johnson (Janssen) | Teclistamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| Johnson & Johnson (Janssen) | JNJ-79635322 Bispecific antibody targeting CD3 and BCMA | CD3E, TNFRSF17 | Phase 3 | Multiple Myeloma; Relapsed or Refractory Multiple Myeloma | Apr 2027 |
| Amgen | Tarlatamab T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent | CD3E, CD3G, CD3D, DLL3 | Phase 3 | Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer … | Apr 2027 |
| Amgen | Blinatumomab T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent | CD3E, CD3G, CD3D, CD19 | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia … | Oct 2027 |
| Johnson & Johnson (Janssen) | Ramantamig BCMAxGPRC5DxCD3 trispecific antibody | TNFRSF17, CD3E, BCMA, GPRC5D | Phase 3 | Multiple Myeloma | Dec 2027 |
| AstraZeneca | surovatamig (AZD0486) Bispecific monoclonal antibody targeting CD20 and CD3E | CD19, CD3E, CD20 | Phase 3 | Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma … | Jan 2028 |
| Astellas | ASP2138 Bispecific antibody binding CLDN18.2 on tumor cells and CD3E on T cells | CD3E, CLDN18 | Phase 3 | Gastric Adenocarcinoma; Pancreatic Ductal Adenocarcinoma | Jan 2028 |
| Regeneron Pharmaceuticals | Odronextamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma … | Feb 2028 |
| Dana-Farber Cancer Institute | Linvoseltamab Bispecific T cell engager targeting CD3 and BCMA | CD3E, BCMA | Phase 3 | Multiple Myeloma | Oct 2033 |
| Institute of Hematology & Blood Diseases Hospital, China | CM336 BCMA/CD3 bispecific antibody | BCMA, CD3E | Phase 2 | Solitary Bone Plasmacytoma; Systemic Light Chain Amyloidosis; POEMS Syndrome; Immune Thrombocytopenia (ITP) … | Dec 2026 |
| University Hospital Tuebingen | CC-1 Bispecific antibody targeting PSMA and CD3 | FOLH1, CD3E | Phase 2 | Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostate Cancer Recurrent | Dec 2026 |
| Keymed Biosciences Co.Ltd | CM336 BCMA/CD3 bispecific antibody | BCMA, CD3E, TNFRSF17 | Phase 2 | Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous Disease | Dec 2026 |
| Mitchell Cairo | alpha beta depletion (α/β CD3+/CD19+ cell depletion) Selective depletion of alpha/beta T cells and CD19+ B cells from donor stem cells for allo | CD3E, CD19 | Phase 2 | Acute Leukemia | Dec 2026 |
| Tiziana Life Sciences | Foralumab (TZLS-401) T cell surface glycoprotein CD3 inhibitor | CD3E, CD3G, CD3D | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple System Atrophy; Dementia | Apr 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | GPRC5D/CD3 BiTEs Bispecific T-cell engager targeting GPRC5D and CD3 | GPRC5D, CD3E | Phase 2 | Multiple Myeloma, Newly Diagnosed; Multiple Myeloma, Plasma Cell Leukemia | Aug 2027 |
| Memorial Sloan Kettering Cancer Center | Elranatamab-bcmm Bispecific antibody targeting BCMA and CD3 | TNFRSF17, CD3E | Phase 2 | Multiple Myeloma | Aug 2029 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Teplizumab T-cell surface glycoprotein CD3 epsilon chain other | CD3E | Phase 2 | Type 1 Diabetes Mellitus | Nov 2029 |
| Multiple Myeloma Research Consortium | Linvoseltamab B-cell maturation antigen (BCMA) × CD3 bispecific monoclonal antibody | TNFRSF17, CD3E | Phase 2 | High Risk Newly Diagnosed Multiple Myeloma | Oct 2035 |
| Immunocore | IMC-R117C PIWIL1 × CD3 bispecific ImmTAC protein | PIWIL1, CD3E | Phase 1 | Cancer | Nov 2026 |
| Johnson & Johnson (Janssen) | JNJ-78278343 KLK2-CD3 bispecific antibody (pasritamig) | KLK2, CD3E | Phase 1 | Prostatic Neoplasms | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | A-319 CD19xCD3 bispecific antibody (T-cell redirecting) | CD19, CD3E | Phase 1 | Systemic Lupus Erythematosus | Dec 2026 |
| Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | MK-4002 (HPN217) Bispecific antibody targeting BCMA and CD3 | BCMA, CD3E | Phase 1 | Multiple Myeloma in Relapse | Dec 2026 |
| Excyte Biopharma | YKST02 BCMA-CD3 bispecific antibody | BCMA, CD3E | Phase 1 | Relapsed or Refractory Multiple Myeloma | Dec 2026 |
| German Cancer Research Center | CC-3 Bispecific CD276xCD3 antibody | CD276, CD3E | Phase 1 | Colorectal Cancer | Mar 2027 |
| Children's Oncology Group | Flotetuzumab Interleukin-3 receptor subunit alpha binding agent; T cell surface glycoprotein CD3 binding agent | IL3RA, CD3E, CD3G, CD3D | Phase 1 | Recurrent Acute Myeloid Leukemia | Mar 2027 |
| NextPoint Therapeutics | NPX372 B7-H7:CD3 bispecific antibody | PDCD7, CD3E | Phase 1 | Metastatic Malignant Neoplasm | Apr 2027 |
| Ruijin Hospital | ABO2203 mRNA encoding CD19/CD3 T cell engager | CD19, CD3E | Phase 1 | B-cell Non-Hodgkin Lymphoma | May 2027 |
| Jeffrey Veale, MD | CD34+ and CD3+ hematopoietic stem/progenitor cells Donor-derived blood stem and T cells for facilitating mixed chimerism and immune tolerance | CD34, CD3E | Phase 1 | Renal Transplant Rejection | May 2027 |
| Mustafa Khasraw, MBChB, MD, FRCP, FRACP | hEGFRvIII-CD3 (BRiTE) Bispecific T cell engager with one arm binding CD3 on T cells and the opposing arm binding | EGFR, CD3E | Phase 1 | Newly Diagnosed Glioblastoma | Dec 2027 |
| Sanofi | SAR448501/DR-0201 Bispecific antibody targeting CD19 and CD3E | CD19, CD3E | Phase 1 | B-cell Non Hodgkin Lymphoma; Systemic Lupus Erythematosus (SLE) | Jan 2028 |
| Shine-On Biomedical | SOA101 Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3 | CD274, HLA-G, CD3E | Phase 1 | Solid Tumors | Feb 2028 |
| Paul Szabolcs | CD3/CD19 depleted leukocytes Negative selection depleting CD3+ and CD19+ T cells and B cells from donor bone marrow via | CD3E, CD19 | Phase 1 | Sickle Cell Anemia | Aug 2028 |
| University of Virginia | CD33 FPBMC anti-CD3 x anti-CD33 bispecific antibody armed fresh peripheral blood mononuclear cells | CD3E, CD33 | Phase 1 | Acute Myeloid Leukemia | Aug 2028 |
| BioAtla | BA3182 Conditionally active bispecific T-cell engager (BiTE) antibody targeting EpCAM and CD3 | EPCAM, CD3E | Phase 1 | Advanced Adenocarcinoma | Sep 2028 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2934 injection Bispecific antibody targeting BCMA and CD3 | BCMA, CD3E | Phase 1 | Systemic Light Chain Amyloidosis | Feb 2029 |
| AstraZeneca | AZD5863 T cell-engaging bi-specific antibody targeting CLDN18.2 and CD3 | CLDN18, CD3E | Phase 1 | Gastric Cancer | Mar 2029 |
| Mabwell (Shanghai) Bioscience | 6MW5311 bispecific T cell engager antibody with bivalent binding to LILRB4 on tumor cells and mono | LILRB4, CD3E | Phase 1 | AML | Dec 2029 |
| Cullinan Therapeutics | CLN-049 FLT3 x CD3 bispecific T cell engager | FLT3, CD3E | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Dec 2029 |
| Guangzhou Excelmab | EX103 CD3 and CD20 bispecific monoclonal antibody | CD3E, CD20 | Phase 1 | CD20-positive Non-Hodgkin Lymphoma | – |
| AbbVie | TNB-383B BCMA x CD3 T-cell engaging bispecific antibody | BCMA, CD3E | Phase 1 | Multiple Myeloma | – |
Multiple Myeloma (75) Follicular Lymphoma (13) Acute Lymphoblastic Leukemia (13) Diffuse Large B-Cell Lymphoma (8) Large B-cell Lymphoma (8) Lymphoma (7) Multiple Myeloma (MM) (6) Relapsed Refractory Multiple Myeloma (RRMM) (6) B Acute Lymphoblastic Leukemia (6) Recurrent Diffuse Large B-Cell Lymphoma (5) B-cell Non-Hodgkin Lymphoma (5) Multiple Myeloma, Newly Diagnosed (5)
mixed (21), small molecule (15), antibody (7), protein or peptide (3), other (2)
Johnson & Johnson (Janssen) (5) Regeneron Pharmaceuticals (2) Amgen (2) Institute of Hematology & Blood Diseases Hospital, China (2) Roche (2) AstraZeneca (2) Tiziana Life Sciences (1) Sanofi (1) Ruijin Hospital (1) Shine-On Biomedical (1) Pfizer (1) Cullinan Therapeutics (1) Wuhan YZY Biopharma (1) Genmab (1) Paul Szabolcs (1) Jeffrey Veale, MD (1) Keymed Biosciences Co.Ltd (1) Astellas (1) German Cancer Research Center (1) Mabwell (Shanghai) Bioscience (1)
CD3G (11) CD3D (11) BCMA (10) TNFRSF17 (8) CD19 (7) MS4A1 (4) GPRC5D (4) CD20 (2) EPCAM (2) CLDN18 (2) DLL3 (1) CD274 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.